Andrew Walters, CEO & Chairman, highlighted that 2025 delivered another strong year, both strategically and financially, stating, “I am pleased to share that we delivered full year 2025 diluted EPS of ...
The diluted loss per share for the three months ended June 30, 2024 was determined excluding the effect of 3.82 million dilutive shares as the impact of such shares would have been antidilutive due to ...
4d
Globus Medical raises 2026 EPS guidance to $4.40-$4.50 with margin gains following record Q4 results
Q4 2025 earnings call recap: revenue/EPS beats, margin expansion, Nevro integration, and raised 2026 guidance—read key takeaways.
Hosted on MSN
Pfizer raises 2025 EPS guidance to $2.90–$3.10 while targeting margin expansion through $7.7B cost savings by 2027
Albert Bourla, Chairman and CEO, highlighted progress in R&D, expansion of the commercial portfolio, and improved margins, stating the company is “raising our adjusted diluted EPS guidance for full ...
Information reconciling certain forward-looking GAAP measures to non-GAAP measures related to FY 2025 guidance, including organic net sales growth, adjusted operating margin and adjusted free cash ...
TYSONS CORNER, Va.--(BUSINESS WIRE)--Strategy Inc (Nasdaq: STRF/STRC/STRK/STRD/MSTR) (“Strategy” or the “Company”), the largest corporate holder of bitcoin ...
Q4 2025 Management View CEO Lynn Bamford opened the call by highlighting a record year, emphasizing that "we continue to deliver on our pivot to growth strategy, which resulted in strong growth in ...
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results